Innoviva INVA
NASDAQ INVA
$21.33 -0.02 (-0.09%)
As of: Sep 4, 2026 · 3:59 PM EDT

Innoviva (INVA) Consolidated Net Income (2010 - 2026)

Innoviva's (INVA) quarterly Consolidated Net Income came in at $186.6 million in Q1 2026, up 500.51% YoY from $31.1 million in Q1 2025, and up 1191.71% on a QoQ basis from -$17.1 million in Q4 2025.

Analysis

Innoviva (INVA) Consolidated Net Income (2010 - 2026) Analysis & Trends

Innoviva (INVA) has 16 years of Consolidated Net Income data on file, last reported at $186.6 million in Q1 2026.

  • Quarterly Consolidated Net Income rose 500.51% year-over-year to $186.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $340.2 million (up 223.11% YoY) and the FY2025 annual result came in at $326.9 million, up 1329.41% from the prior year.
  • Consolidated Net Income advanced to $186.6 million in Q1 2026, from -$17.1 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $288.6 million in Q3 2022 to a low of -$198.2 million in Q4 2024.
  • A 5-year average of $33.9 million and a median of $21.4 million in 2022 frame the typical range for Consolidated Net Income.
  • Annual changes were most pronounced in 2024 — Consolidated Net Income slumped 2757.85% — and 2025, when it soared 3359.15%.
  • Tracing INVA's Consolidated Net Income over 5 years: stood at -$15.9 million in 2022, then jumped by 36.0% to -$10.2 million in 2023, then tumbled by 1847.08% to -$198.2 million in 2024, then surged by 91.38% to -$17.1 million in 2025, then jumped by 1191.71% to $186.6 million in 2026.
  • The last three Consolidated Net Income figures came in at $186.6 million (Q1 2026), -$17.1 million (Q4 2025), and $107.0 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Innoviva 1.56 Bn 984.81 Mn 90.62 Mn -83.42 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -83.42 Mn
Mar 31, 2026 186.56 Mn
Dec 31, 2025 -13.82 Mn
Sep 30, 2025 107.01 Mn
Jun 30, 2025 63.69 Mn
Mar 31, 2025 -46.59 Mn
Dec 31, 2024 -10.54 Mn
Sep 30, 2024 3.06 Mn
Jun 30, 2024 -34.68 Mn
Mar 31, 2024 36.52 Mn
Dec 31, 2023 -6.58 Mn
Sep 30, 2023 118.19 Mn
Jun 30, 2023 1.28 Mn
Mar 31, 2023 34.84 Mn
Dec 31, 2022 -10.33 Mn
Sep 30, 2022 288.54 Mn
Jun 30, 2022 21.40 Mn
Mar 31, 2022 37.82 Mn
Dec 31, 2021 -6.05 Mn
Sep 30, 2021 323.19 Mn